Bausch & Lomb Corp (BLCO) Stock Price, Quote & News

Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeut...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 905 695 7700

Website: www.bausch.com

Address:

520 Applewood Crescent, Vaughan, Canada

TickrTalk0007 Jun. 15 at 3:39 AM

$BLCO worthless company with sh*tty products. Fire the BD and Corp strategy team

0 · Reply

TraderJoe65 Jun. 10 at 2:58 AM

$LENZ in what world does $BLCO not buy this outright

2 · Reply

Aldinho_lbk May. 28 at 2:43 PM

$OTLK the fact institutional investors are on board after learning FDA approval towards "final labeling", directors have more skin in the game, and Baush and Lomb $BLCO is the potential candidate according to Claude AI, makes this stock a preferred investment for this upcoming month.

0 · Reply

CgI86 May. 28 at 6:49 AM

$BHC $BLCO $COO

0 · Reply

Aldinho_lbk May. 27 at 8:25 PM

$OTLK according to Claude, the likelihood of institutions acquiring $OTLK shares in the open market are higher because "undervalue". Baush and Lomb $BLCO may be the partnership needed.

0 · Reply

Aldinho_lbk May. 26 at 4:15 PM

$OTLK people taking a sip on speculative take over, with Roche $RHHBY as potential candidate. Allow me to differ. ALCON $ALC and Baush Lamb $BLCO are more suitable partners here in the USA, even for a M&A...

1 · Reply

NVDAMillionaire May. 13 at 8:29 PM

$BLCO Great piece that accurately captures BLCO's current position. So if you want to refresh your understanding of BLCO or learn about BLCO for the first time, this is essential reading. https://everyticker.com/quote/BLCO/analysis/margin-inflection-meets-portfolio-diversification-at-bausch-lomb-nyse-blco

0 · Reply

Stock_Spectator May. 13 at 4:08 AM

$BLCO - so much for another Tuesday….

1 · Reply

Davidhansraj May. 7 at 12:51 AM

$BLCO oh don’t torture him his prediction was full of heart

0 · Reply

Stock_Spectator May. 5 at 2:39 PM

$BLCO maybe this Tuesday? Oh, right, that’s today…..

0 · Reply

Bausch + Lomb Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 1, 2026, 1:00 PM EDT - 15 days ago

Bausch + Lomb Transcript: R&D Day 2026

Jun 1, 2026, 1:00 PM EDT - 15 days ago

Bausch + Lomb Slides: FY 2026

Jun 1, 2026, 6:59 AM EDT - 15 days ago

Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States

May 21, 2026, 7:15 AM EDT - 26 days ago

Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 20, 2026, 4:49 PM EDT - 27 days ago

Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results

May 20, 2026, 10:30 AM EDT - 27 days ago

Bausch + Lomb Transcript: AGM 2026

2026-05-19T11:10:10.000Z - 4 weeks ago

Bausch + Lomb announces U.S. launch of PreserVision AREDS3

2026-05-07T14:16:04.000Z - 5 weeks ago

Bausch + Lomb launches Bi-Blade+ dual-port vitrectomy cutter in Europe

May 6, 2026, 7:15 AM EDT - 5 weeks ago

Bausch + Lomb Announces Second R&D “Teach-in” Webinar

2026-04-30T16:45:33.000Z - 6 weeks ago

Bausch + Lomb price target lowered to $16 from $17 at Evercore ISI

2026-04-30T14:24:47.000Z - 6 weeks ago

Bausch + Lomb price target lowered to $16 from $18 at Deutsche Bank

2026-04-30T11:48:27.000Z - 6 weeks ago

Bausch + Lomb price target lowered to C$19 from C$21 at Citi

Apr 30, 2026, 7:00 AM EDT - 6 weeks ago

Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting

Apr 29, 2026, 8:00 AM EDT - 6 weeks ago

Bausch + Lomb Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 6 weeks ago

Bausch + Lomb Earnings release: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 6 weeks ago

Bausch + Lomb Slides: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 6 weeks ago

Bausch + Lomb Quarterly report: Q1 2026

2026-04-29T11:55:45.000Z - 6 weeks ago

Bausch + Lomb reports Q1 adjusted EPS 5c, consensus 5c

2026-04-29T11:51:53.000Z - 6 weeks ago

Bausch + Lomb raises FY26 revenue view to $5.420B-$5.530B from $5.375B-$5.475B

Apr 29, 2026, 6:58 AM EDT - 6 weeks ago

Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook

2026-04-23T11:15:36.000Z - 7 weeks ago

Bausch + Lomb announces narrative review on certain B vitamins

Apr 22, 2026, 7:15 AM EDT - 7 weeks ago

Bausch + Lomb Releases 2025 Sustainability Impact Report

2026-04-16T11:23:23.000Z - 2 months ago

Bausch + Lomb reports nearly 725k lbs. of eye care materials recycled

Apr 16, 2026, 7:00 AM EDT - 2 months ago

Bausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling Program

Apr 10, 2026, 8:00 AM EDT - 2 months ago

Bausch + Lomb Proxy statement: Proxy filing

2026-04-08T11:16:31.000Z - 2 months ago

Bausch + Lomb receives FDA 510k clearance for Bi-Blade+

2026-04-07T11:29:47.000Z - 2 months ago

Bausch + Lomb announces European availability of enVista Envy lenses

2026-04-06T12:24:21.000Z - 2 months ago

Bausch + Lomb price target lowered to $17 from $17.50 at Evercore ISI

$Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting$

Apr 6, 2026, 7:00 AM EDT - 2 months ago

Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting

Mar 30, 2026, 7:15 AM EDT - 2 months ago

Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29

Mar 23, 2026, 1:30 PM EDT - 3 months ago

Bausch + Lomb Transcript: Status update

Mar 23, 2026, 1:30 PM EDT - 3 months ago

Bausch + Lomb Press release: Status update

Mar 23, 2026, 1:30 PM EDT - 3 months ago

Bausch + Lomb Slides: Status update

2026-03-23T11:05:32.000Z - 3 months ago

Bausch + Lomb announces 24-month U.S. data on ELIOS system in Glaucoma

Mar 23, 2026, 7:00 AM EDT - 3 months ago

Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma

Mar 13, 2026, 9:00 AM EDT - 3 months ago

Bausch + Lomb Corporation Investigated by the Portnoy Law Firm

Mar 9, 2026, 7:15 AM EDT - 3 months ago

Bausch + Lomb Launches R&D “Teach-in” Webinar Series

2026-02-25T15:05:56.000Z - 3 months ago

Trump Trade: L’Oreal, Bausch + Lomb sue for Trump tariff refunds

BAC C COST FDX GS GT IBM

2026-02-24T21:00:27.000Z - 4 months ago

L’Oreal, Bausch + Lomb sue for Trump tariff refunds, Reuters reports

COST FDX GT

Feb 24, 2026, 7:00 AM EST - 4 months ago

Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®

2026-02-23T13:32:50.000Z - 4 months ago

Bausch + Lomb price target raised to $20 from $17 at H.C. Wainwright

2026-02-19T14:06:13.000Z - 4 months ago

Bausch + Lomb price target raised to $15 from $13 at BofA

BHC

2026-02-19T12:35:34.000Z - 4 months ago

Bausch + Lomb price target raised to $18 from $15 at Deutsche Bank

2026-02-19T12:34:14.000Z - 4 months ago

Bausch + Lomb price target raised to $16 from $15 at Stifel

2026-02-19T11:52:08.000Z - 4 months ago

Bausch + Lomb price target raised to $21 from $20 at Citi

Feb 18, 2026, 8:00 AM EST - 4 months ago

Bausch + Lomb Earnings Call Transcript: Q4 2025

Feb 18, 2026, 8:00 AM EST - 4 months ago

Bausch + Lomb Annual report: Q4 2025

Feb 18, 2026, 8:00 AM EST - 4 months ago

Bausch + Lomb Earnings release: Q4 2025

Feb 18, 2026, 8:00 AM EST - 4 months ago

Bausch + Lomb Slides: Q4 2025

Feb 18, 2026, 6:58 AM EST - 4 months ago

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance

Jan 20, 2026, 7:15 AM EST - 5 months ago

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18

Jan 12, 2026, 4:30 PM EST - 5 months ago

Bausch + Lomb Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 4:30 PM EST - 5 months ago

Bausch + Lomb Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 5 months ago

Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.

Jan 2, 2026, 4:30 PM EST - 5 months ago

Bausch + Lomb Completes Refinancing of Outstanding Term B Loans

Dec 23, 2025, 7:30 AM EST - 6 months ago

Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 4:30 PM EST - 6 months ago

Bausch + Lomb Announces Two Board of Directors Appointments

Dec 12, 2025, 4:48 PM EST - 6 months ago

Bausch + Lomb Announces Refinancing of Outstanding Term B Loans

Dec 3, 2025, 9:00 AM EST - 6 months ago

Bausch + Lomb Transcript: Citi Annual Global Healthcare Conference 2025

Nov 18, 2025, 4:30 PM EST - 7 months ago

Bausch + Lomb to Participate in Citi Global Healthcare Conference

Nov 13, 2025, 8:30 AM EST - 7 months ago

Bausch + Lomb Transcript: Investor Day 2025

Nov 13, 2025, 8:30 AM EST - 7 months ago

Bausch + Lomb Slides: FY 2025

Nov 10, 2025, 6:59 AM EST - 7 months ago

Bausch + Lomb Reports More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling Program

Oct 29, 2025, 8:00 AM EDT - 8 months ago

Bausch + Lomb Earnings Call Transcript: Q3 2025

Oct 29, 2025, 8:00 AM EDT - 8 months ago

Bausch + Lomb Quarterly report: Q3 2025

Oct 29, 2025, 8:00 AM EDT - 8 months ago

Bausch + Lomb Earnings release: Q3 2025

Oct 29, 2025, 8:00 AM EDT - 8 months ago

Bausch + Lomb Slides: Q3 2025

Oct 29, 2025, 6:58 AM EDT - 8 months ago

Bausch + Lomb Announces Third-Quarter 2025 Results

Oct 19, 2025, 8:00 PM EDT - 8 months ago

Activist Jana Takes Stake in Cooper, a Maker of Medical Devices

COO

Sep 29, 2025, 7:15 AM EDT - 9 months ago

Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13

Sep 8, 2025, 7:45 AM EDT - 10 months ago

Bausch + Lomb Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 7:00 AM EDT - 10 months ago

Bausch + Lomb Launches ASANA™ Gas Permeable Lenses in the United States

Aug 18, 2025, 5:01 PM EDT - 10 months ago

Bausch + Lomb Announces Board Changes

Aug 14, 2025, 7:15 AM EDT - 10 months ago

Bausch + Lomb to Participate in Upcoming Investor Conferences

Jul 30, 2025, 8:00 AM EDT - 11 months ago

Bausch + Lomb Earnings Call Transcript: Q2 2025

Jul 30, 2025, 8:00 AM EDT - 11 months ago

Bausch + Lomb Quarterly report: Q2 2025

Jul 30, 2025, 8:00 AM EDT - 11 months ago

Bausch + Lomb Earnings release: Q2 2025

Jul 30, 2025, 8:00 AM EDT - 11 months ago

Bausch + Lomb Slides: Q2 2025

Jul 30, 2025, 6:57 AM EDT - 11 months ago

Bausch + Lomb Announces Second-Quarter 2025 Results

Jul 1, 2025, 7:00 AM EDT - 1 year ago

Bausch + Lomb Combines Patient Voices and New Survey Insights to Combat Persistent Misconceptions about Dry Eye

Jun 30, 2025, 6:58 AM EDT - 1 year ago

Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13

Jun 18, 2025, 4:30 PM EDT - 1 year ago

Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering

Jun 10, 2025, 8:48 AM EDT - 1 year ago

Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement

Jun 4, 2025, 7:35 AM EDT - 1 year ago

Bausch + Lomb Transcript: Jefferies Global Healthcare Conference 2025

May 22, 2025, 7:30 AM EDT - 1 year ago

Bausch + Lomb to Participate in the 2025 Jefferies Global Healthcare Conference

May 21, 2025, 4:30 PM EDT - 1 year ago

Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results

May 21, 2025, 8:00 AM EDT - 1 year ago

Bausch + Lomb Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Bausch + Lomb Earnings Call Transcript: Q1 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Bausch + Lomb Quarterly report: Q1 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Bausch + Lomb Earnings release: Q1 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Bausch + Lomb Slides: Q1 2025

Apr 30, 2025, 6:57 AM EDT - 1 year ago

Bausch + Lomb Announces First-Quarter 2025 Results

TickrTalk0007 Jun. 15 at 3:39 AM

$BLCO worthless company with sh*tty products. Fire the BD and Corp strategy team

0 · Reply

TraderJoe65 Jun. 10 at 2:58 AM

$LENZ in what world does $BLCO not buy this outright

2 · Reply

Aldinho_lbk May. 28 at 2:43 PM

0 · Reply

CgI86 May. 28 at 6:49 AM

$BHC $BLCO $COO

0 · Reply

Aldinho_lbk May. 27 at 8:25 PM

$OTLK according to Claude, the likelihood of institutions acquiring $OTLK shares in the open market are higher because "undervalue". Baush and Lomb $BLCO may be the partnership needed.

0 · Reply

Aldinho_lbk May. 26 at 4:15 PM

1 · Reply

NVDAMillionaire May. 13 at 8:29 PM

0 · Reply

Stock_Spectator May. 13 at 4:08 AM

$BLCO - so much for another Tuesday….

1 · Reply

Davidhansraj May. 7 at 12:51 AM

$BLCO oh don’t torture him his prediction was full of heart

0 · Reply

Stock_Spectator May. 5 at 2:39 PM

$BLCO maybe this Tuesday? Oh, right, that’s today…..

0 · Reply

PenkeInvesting Apr. 30 at 7:26 PM

Fundamental analysis of $BLCO (Bausch & Lomb Corp) based on financial data and reported results. #BLCO

0 · Reply

Stock_Spectator Apr. 29 at 2:08 PM

$BLCO earnings call was an easy short. Then will drive $BHC to financial ruin.

0 · Reply

StocktwitsEarnings Apr. 29 at 1:16 PM

$BLCO Q1 '26 Earnings Results & Recap Bausch + Lomb raised its full-year 2026 revenue guidance to $5.420B-$5.520B, with 5.3-7.2% constant currency growth, and adjusted EBITDA excluding acquired IPR&D to $1.010B-$1.060B.

0 · Reply

Stock_Spectator Apr. 28 at 11:48 AM

$BLCO it’s Tuesday again. The only announcement will be another huge quarterly loss and unmanageable debt pile.

1 · Reply

Axos300 Apr. 27 at 1:40 PM

$BLCO They have to come up with 10 billion in 2027. 2.5 billion of which is due February 17th 2027. Bankruptcy is in their future.

0 · Reply

Stock_Spectator Apr. 23 at 5:30 PM

$BLCO maybe back to the $10 range and then $BHC is out of financing options.

0 · Reply

Stock_Spectator Apr. 23 at 4:51 PM

$BLCO once the short side drives this low enough, the whole house of cards falls apart with $BHC forced into bankruptcy

0 · Reply

Stock_Spectator Apr. 22 at 3:16 PM

$BLCO so you were shorting into your acquisition assertions ?

0 · Reply

Stock_Spectator Apr. 21 at 2:59 PM

$BLCO it is Tuesday….again….

0 · Reply

CgI86 Apr. 14 at 7:53 PM

$BLCO $BHC $COO In the recently published BHC ANNUAL Financial Report ARS it is stated in the financials that there are gains from the divestment and discontinuation of the Vision business unit! When can COO and BLCO finally announce and stop withholding information from investors?

1 · Reply

Contrarian_Dan Apr. 13 at 12:36 PM

$BLCO 20s inbound.

0 · Reply

CgI86 Apr. 11 at 8:02 AM

$BLCO $BLCO $COO $BHC The two new CEOs for the newly separated COOPERVISION are from what company? BLCO That is right! BLCO and COOPER VISION merger is imminent in my humble opinion

1 · Reply

Market Cap	5.38B
Revenue (ttm)	5.10B
Net Income (ttm)	-360.00M
EPS (ttm)	N/A
PE Ratio	23.52
Forward PE	18.59
Profit Margin	-7.06%
Debt to Equity Ratio	0.79

Volume	397,367
Avg Vol	452,004
Day's Range	N/A - N/A
Shares Out	357.04M
Stochastic %K	29%
Beta	0.58
Analysts	Sell
Price Target	$18.00